These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 9870683)

  • 1. Overexpression of c-met proto-oncogene associated with chromophilic renal cell carcinoma with papillary growth.
    Inoue K; Karashima T; Chikazawa M; Iiyama T; Yoshikawa C; Furihata M; Ohtsuki Y; Shuin T
    Virchows Arch; 1998 Dec; 433(6):511-5. PubMed ID: 9870683
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The expression pattern of Von Hippel-Lindau tumor suppressor protein, MET proto-oncogene, and TFE3 transcription factor oncoprotein in renal cell carcinoma in Upper Egypt.
    Nagi FM; Omar AA; Mostafa MG; Mohammed EA; Abd-Elwahed Hussein MR
    Ultrastruct Pathol; 2011 Apr; 35(2):79-86. PubMed ID: 21299348
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinicopathologic and molecular genetic study of renal cell carcinoma occurring in teenagers].
    Rao Q; Zhou J; Zhang RS; Ma HH; Zhou HB; Lu ZF; Zhou XJ
    Zhonghua Bing Li Xue Za Zhi; 2010 Sep; 39(9):582-6. PubMed ID: 21092583
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic inactivation of the RASSF1A 3p21.3 tumor suppressor gene in both clear cell and papillary renal cell carcinoma.
    Morrissey C; Martinez A; Zatyka M; Agathanggelou A; Honorio S; Astuti D; Morgan NV; Moch H; Richards FM; Kishida T; Yao M; Schraml P; Latif F; Maher ER
    Cancer Res; 2001 Oct; 61(19):7277-81. PubMed ID: 11585766
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting the hepatocyte growth factor/c-Met signaling pathway in renal cell carcinoma.
    Harshman LC; Choueiri TK
    Cancer J; 2013; 19(4):316-23. PubMed ID: 23867513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MET expression in sporadic renal cell carcinomas.
    Choi JS; Kim MK; Seo JW; Choi YL; Kim DH; Chun YK; Ko YH
    J Korean Med Sci; 2006 Aug; 21(4):672-7. PubMed ID: 16891811
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of HGF/SF and Met protein is associated with genetic alterations of VHL gene in primary renal cell carcinomas.
    Oh RR; Park JY; Lee JH; Shin MS; Kim HS; Lee SK; Kim YS; Lee SH; Lee SN; Yang YM; Yoo NJ; Lee JY; Park WS
    APMIS; 2002 Mar; 110(3):229-38. PubMed ID: 12076276
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Vascular endothelial growth factor-B and vascular endothelial growth factor-C expression in renal cell carcinomas: regulation by the von Hippel-Lindau gene and hypoxia.
    Gunningham SP; Currie MJ; Han C; Turner K; Scott PA; Robinson BA; Harris AL; Fox SB
    Cancer Res; 2001 Apr; 61(7):3206-11. PubMed ID: 11306510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of the angiopoietins and their receptor Tie2 in human renal clear cell carcinomas; regulation by the von Hippel-Lindau gene and hypoxia.
    Currie MJ; Gunningham SP; Turner K; Han C; Scott PA; Robinson BA; Chong W; Harris AL; Fox SB
    J Pathol; 2002 Dec; 198(4):502-10. PubMed ID: 12434420
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathologic Analysis of PD-L1 and PD-L2 Expression in Renal Cell Carcinoma: Association with Oncogenic Proteins Status.
    Shin SJ; Jeon YK; Kim PJ; Cho YM; Koh J; Chung DH; Go H
    Ann Surg Oncol; 2016 Feb; 23(2):694-702. PubMed ID: 26464193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential response to transforming growth factor (TGF)-alpha and fibroblast growth factor (FGF) in human renal cell carcinomas of the clear cell and papillary types.
    Ramp U; Reinecke P; Gabbert HE; Gerharz CD
    Eur J Cancer; 2000 May; 36(7):932-41. PubMed ID: 10785600
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular genetics of renal carcinogenesis.
    Walker C
    Toxicol Pathol; 1998; 26(1):113-20. PubMed ID: 9502393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor suppressor activity and epigenetic inactivation of hepatocyte growth factor activator inhibitor type 2/SPINT2 in papillary and clear cell renal cell carcinoma.
    Morris MR; Gentle D; Abdulrahman M; Maina EN; Gupta K; Banks RE; Wiesener MS; Kishida T; Yao M; Teh B; Latif F; Maher ER
    Cancer Res; 2005 Jun; 65(11):4598-606. PubMed ID: 15930277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunodetection of c-met-oncogene's protein product in renal cell neoplasia.
    Nakopoulou L; Vouriakou C; Papaliodi E; Lazaris AC; Stefanaski K; Michalopoulos G
    Pathol Res Pract; 1997; 193(4):299-304. PubMed ID: 9258956
    [TBL] [Abstract][Full Text] [Related]  

  • 15. c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma.
    Gibney GT; Aziz SA; Camp RL; Conrad P; Schwartz BE; Chen CR; Kelly WK; Kluger HM
    Ann Oncol; 2013 Feb; 24(2):343-349. PubMed ID: 23022995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Topotecan (Hycamtin) responsiveness in human renal carcinoma cell lines of the clear cell and papillary types.
    Ramp U; Mahotka C; Kalinski T; Ebel E; Gabbert HE; Gerharz CD
    Anticancer Res; 2001; 21(5):3509-17. PubMed ID: 11848517
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Somatic von Hippel-Lindau disease gene mutation in clear-cell renal carcinomas associated with end-stage renal disease/acquired cystic disease of the kidney.
    Yoshida M; Yao M; Ishikawa I; Kishida T; Nagashima Y; Kondo K; Nakaigawa N; Hosaka M
    Genes Chromosomes Cancer; 2002 Dec; 35(4):359-64. PubMed ID: 12378530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. C-kit expression in renal oncocytomas and chromophobe renal cell carcinomas.
    Huo L; Sugimura J; Tretiakova MS; Patton KT; Gupta R; Popov B; Laskin WB; Yeldandi A; Teh BT; Yang XJ
    Hum Pathol; 2005 Mar; 36(3):262-8. PubMed ID: 15791570
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic basis of cancer of the kidney: disease-specific approaches to therapy.
    Linehan WM; Vasselli J; Srinivasan R; Walther MM; Merino M; Choyke P; Vocke C; Schmidt L; Isaacs JS; Glenn G; Toro J; Zbar B; Bottaro D; Neckers L
    Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6282S-9S. PubMed ID: 15448018
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Overproduction of vascular endothelial growth factor related to von Hippel-Lindau tumor suppressor gene mutations and hypoxia-inducible factor-1 alpha expression in renal cell carcinomas.
    Na X; Wu G; Ryan CK; Schoen SR; di'Santagnese PA; Messing EM
    J Urol; 2003 Aug; 170(2 Pt 1):588-92. PubMed ID: 12853836
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.